The CHIPS Trial (Control of Hypertension In Pregnancy Study)

• Conditions: chronic hypertension; gestational hypertension; 10026908; 10057166

• Registration Number: NL-OMON35551
• Lead Sponsor: THE UNIVERSITY OF BRITISH COLUMBIA, Departments of Obstetrics and Gynaecology & Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 220

Inclusion Criteria

pre-existing/gestational hypertension; office dBP 90-105mmHg (or dBP 85-105mmHg if on antihypertensive medication); live fetus; and 14-33+6 weeks.

Exclusion Criteria

Severe systolic hypertension; proteinuria; contraindication to either arm of trial or to prolongation of pregnancy; ACE inhibitor use in pregnancy; known multiple gestation or lethal/major fetal anomaly; plan to terminate pregnancy; or prior participation in CHIPS.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pregnancy loss (miscarriage, pregnancy termination, stillbirth, or neonatal<br /><br>death) or NICU admission for >48hr in the first 28 days of life or prior to<br /><br>primary hospital discharge, whichever is later. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary: One/more serious maternal complication(s) until six weeks postpartum<br /><br>(Section 2.8.2, Table 3). </p><br>